| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | -21.26% | JP Morgan | $17 → $14 | Maintains | Underweight |
| 08/07/2023 | -4.39% | JP Morgan | $18 → $17 | Maintains | Underweight |
| 07/24/2023 | 57.48% | Goldman Sachs | $25 → $28 | Maintains | Buy |
| 07/21/2023 | 57.48% | Goldman Sachs | $25 → $28 | Maintains | Buy |
| 05/24/2023 | 40.61% | Goldman Sachs | $18 → $25 | Maintains | Buy |
| 05/23/2023 | 40.61% | Goldman Sachs | $18 → $25 | Upgrades | Sell → Buy |
| 05/04/2023 | 1.24% | Goldman Sachs | $20 → $18 | Maintains | Sell |
| 05/04/2023 | 34.98% | Stephens & Co. | → $24 | Reiterates | → Equal-Weight |
| 03/06/2023 | 34.98% | Stephens & Co. | $17 → $24 | Maintains | Equal-Weight |
| 03/03/2023 | 51.86% | Raymond James | $25 → $27 | Maintains | Outperform |
| 01/18/2023 | 40.61% | Raymond James | → $25 | Upgrades | Market Perform → Outperform |
| 11/02/2022 | 40.61% | SVB Leerink | $27 → $25 | Maintains | Market Perform |
| 10/06/2022 | 23.73% | Stephens & Co. | → $22 | Initiates Coverage On | → Equal-Weight |
| 08/05/2022 | 68.73% | SVB Leerink | $26 → $30 | Maintains | Market Perform |
| 05/05/2022 | 46.23% | SVB Leerink | $29 → $26 | Maintains | Market Perform |
| 04/19/2022 | 29.36% | Goldman Sachs | $26 → $23 | Maintains | Sell |
| 11/03/2021 | 96.85% | SVB Leerink | $36 → $35 | Maintains | Market Perform |
| 06/15/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 06/03/2021 | 40.61% | Goldman Sachs | → $25 | Initiates Coverage On | → Sell |
| 02/24/2021 | 85.6% | SVB Leerink | $20 → $33 | Maintains | Market Perform |
| 05/06/2020 | -32.51% | JP Morgan | $14 → $12 | Maintains | Underweight |
| 04/02/2020 | -26.88% | B of A Securities | $16 → $13 | Reiterates | → Underperform |
| 03/26/2020 | -43.76% | Barclays | $14 → $10 | Maintains | Underweight |
| 09/26/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 08/14/2019 | 96.85% | Deutsche Bank | $45 → $35 | Maintains | Hold |
| 08/14/2019 | 124.97% | Piper Sandler | $45 → $40 | Downgrades | Overweight → Equal-Weight |
| 08/05/2019 | 153.09% | Deutsche Bank | $32 → $45 | Maintains | Hold |
| 08/02/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 07/29/2019 | — | Needham | Downgrades | Strong Buy → Hold | |
| 07/09/2019 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 01/04/2019 | — | Cowen & Co. | Upgrades | Market Perform → Outperform | |
| 01/03/2019 | 18.11% | Barclays | $23 → $21 | Maintains | Underweight |
| 01/03/2019 | 102.47% | Needham | → $36 | Initiates Coverage On | → Strong Buy |
| 11/30/2018 | 79.98% | Goldman Sachs | $28 → $32 | Upgrades | Sell → Neutral |
What is the target price for Myriad Genetics (MYGN)?
The latest price target for Myriad Genetics (NASDAQ: MYGN) was reported by JP Morgan on November 7, 2023. The analyst firm set a price target for $14.00 expecting MYGN to fall to within 12 months (a possible -21.26% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Myriad Genetics (MYGN)?
The latest analyst rating for Myriad Genetics (NASDAQ: MYGN) was provided by JP Morgan, and Myriad Genetics maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Myriad Genetics (MYGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Myriad Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Myriad Genetics was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Myriad Genetics (MYGN) correct?
While ratings are subjective and will change, the latest Myriad Genetics (MYGN) rating was a maintained with a price target of $17.00 to $14.00. The current price Myriad Genetics (MYGN) is trading at is $17.78, which is out of the analyst's predicted range.